Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)13.70m
- Net income in SEK-13.04m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center Goteborg,Massans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Phone+46 703319051
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Magle Chemoswed Holding AB | 292.44m | -26.60m | 237.47m | 144.00 | -- | 0.4466 | 8.57 | 0.812 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Extrawell Pharmaceutical Holdings Ltd | 60.10m | -385.76m | 241.63m | 161.00 | -- | 0.2371 | -- | 4.02 | -0.1351 | -0.1352 | 0.0219 | 0.3501 | 0.0422 | 10.54 | 5.89 | 322,975.50 | -27.00 | 3.07 | -28.13 | 3.21 | 42.41 | 47.65 | -640.53 | 59.77 | 13.00 | -0.037 | 0.146 | -- | -6.21 | -6.50 | 236.70 | 21.75 | 80.07 | -- |
| Little Green Pharma Ltd | 243.56m | 37.05m | 241.74m | -- | 6.46 | 0.4442 | 3.94 | 0.9925 | 0.0194 | 0.0194 | 0.1268 | 0.2814 | 0.4262 | 0.8199 | 14.01 | -- | 6.48 | -- | 7.09 | -- | 67.46 | -- | 15.21 | -- | 0.8728 | -4.71 | 0.0541 | -- | 43.67 | -- | 140.77 | -- | -- | -- |
| Medicus Pharma Ltd | -892.19bn | -892.19bn | 241.99m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0434 | -- | -- | -- | -- | -- | -361.95 | -- | -- | -- | -- | -- | -- | -- | -- | 1.13 | -- | -- | -- | -109.90 | -- | -- | -- |
| Cilo Cybin Holdings Ltd | 10.41m | -119.75m | 244.45m | -- | -- | 5.44 | -- | 23.49 | -2.88 | -2.88 | 0.2619 | 0.3477 | 0.2187 | -- | 2.55 | -- | -251.63 | -- | -260.31 | -- | 60.64 | -- | -1,150.51 | -- | 16.04 | -- | 0.0532 | -- | -- | -- | -228.61 | -- | -- | -- |
| Lyka Labs Ltd | 131.58m | -642.43k | 245.91m | 499.00 | -- | -- | 33.39 | 1.87 | -0.1801 | -0.1801 | 37.32 | -- | -- | -- | -- | 2,682,217.00 | -- | 2.35 | -- | 3.44 | 60.96 | 61.79 | -0.2546 | 3.29 | -- | -0.3263 | -- | -- | 24.55 | 17.63 | 421.84 | -- | 70.13 | -- |
| Vaidya Sane Ayurved Laboratories Ltd | 96.33m | 8.57m | 246.92m | 636.00 | 30.89 | 3.71 | 18.00 | 2.56 | 7.73 | 7.73 | 85.76 | 64.41 | 1.27 | 4.62 | 15.21 | -- | 11.32 | 7.04 | 13.25 | 9.52 | 83.84 | 73.31 | 8.91 | 4.29 | 2.32 | 84.89 | 0.0092 | -- | -9.55 | 3.61 | 260.35 | -- | 17.02 | -- |
| Elicera Therapeutics AB | 13.70m | -13.04m | 247.53m | 2.00 | -- | 8.08 | -- | 18.07 | -0.3434 | -0.3434 | 0.3712 | 0.6314 | 0.4004 | -- | 9.61 | 6,848,050.00 | -38.14 | -42.99 | -48.58 | -55.48 | -- | -- | -95.24 | -345.69 | -- | -- | 0.00 | -- | -36.52 | -- | 1.75 | -- | -- | -- |
| CRUSHMETRIC Group Ltd | -1.22tn | -1.22tn | 251.92m | 17.00 | -- | 1.25 | -- | -- | -- | -- | -- | 0.0678 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.027 | -- | 0.0898 | -- | -- | -- | -- | -- | -- | -- |
| Tianda Pharmaceuticals Ltd | 354.49m | -76.92m | 252.83m | 624.00 | -- | 0.4557 | -- | 0.7132 | -0.0313 | -0.0313 | 0.1444 | 0.226 | 0.3931 | 2.84 | 5.14 | 442,937.20 | -8.57 | -- | -12.38 | -- | 42.76 | -- | -21.80 | -- | 0.6900 | -15.81 | 0.2183 | -- | -37.99 | -- | -154.07 | -- | -- | -- |
| TherapeuticsMD Inc | 24.95m | 651.30k | 256.10m | 1.00 | 397.44 | 1.05 | 62.40 | 10.27 | 0.0062 | 0.0261 | 0.2419 | 2.37 | 0.0715 | -- | 0.8002 | 2,796,000.00 | 0.1867 | -42.65 | 0.2169 | -112.14 | -- | -- | 2.61 | -193.47 | -- | -5,240.00 | 0.00 | -- | 35.25 | -48.72 | 69.97 | -- | -- | -- |
| Nectar Lifesciences Ltd | 704.93m | -123.89m | 259.53m | 1.79k | -- | -- | -- | 0.3682 | -5.64 | -15.87 | 32.08 | -- | -- | -- | -- | 4,014,993.00 | -- | -1.57 | -- | -2.87 | -7.31 | 15.34 | -17.57 | -2.24 | -- | -3.77 | -- | -- | -0.838 | -6.73 | -2,375.90 | -- | -4.37 | -- |
